Company Insights

CTNM supplier relationships

Explore interactive graphBrowse insights index
CTNM supplier relationship map

CTNM supplier map: where Contineum’s runways and single points of failure live

Contineum Therapeutics (CTNM) is a clinical-stage biotech that discovers and develops oral small-molecule therapies in neuroscience, inflammation and immunology. The company monetizes through partnered development and future commercialization rights, licensing arrangements, and capital markets activity to fund R&D while programs are pre-revenue — making its supplier and banking relationships direct drivers of both operational continuity and financing runway. Explore the full supplier profile at https://nullexposure.com/ for deeper counterparties intelligence.

Why supplier relationships matter for a clinical-stage biotech

Contineum operates without internal commercial manufacturing capacity and relies on third parties for cGMP clinical supplies and for clinical execution. That operating model creates a distinctive contracting posture: high dependence on contract manufacturers and service providers, concentrated supplier footprints, and material operational criticality tied to clinical timelines. The company’s disclosures identify a sole third‑party API manufacturer in China for PIPE-791 and rely on multiple CROs and CMOs to run trials and produce material — a structure that amplifies single‑vendor risk and links regulatory progress directly to supplier performance (10‑K, FY2024).

  • Concentration and geography. Manufacturing for PIPE‑791 is performed in China, making APAC a material location for supply chain resilience.
  • Criticality. Management states a disruption at its CMO could materially impair business results and clinical progress.
  • Contracting posture and maturity. Relationships are standard commercial contracts for CMOs/CROs, active and ongoing while the company advances clinical programs.
  • Spend and scale. Public disclosures emphasize lease commitments and routine third‑party spend consistent with a mid‑range spend band (~$1M–$10M), reflecting a supplier base that is significant but not yet at commercial scale.

These supplier signals are company‑level; where the filings name specific counterparties, the operational implications are direct and specific. See the supplier roster and relationship summaries below, and find additional counterparty intelligence at https://nullexposure.com/.

Counterparties and what they imply for CTNM’s execution

Goldman Sachs & Co. LLC

Goldman Sachs is listed as a joint book-running manager on Contineum’s announced proposed $75.0 million public offering, placing the bank among the primary capital‑markets partners executing the company’s equity raise (BioSpace press release, Mar 9, 2026).

Leerink Partners

Leerink Partners joined as a joint book-running manager for the $75.0 million offering, indicating active placement support and syndicate coverage for CTNM’s financing strategy (BioSpace press release, Mar 9, 2026).

Stifel

Stifel is also a joint book-running manager on the $75.0 million proposed offering, contributing distribution capabilities that expand investor access to CTNM shares in the financing (BioSpace press release, Mar 9, 2026).

RBC Capital Markets

RBC Capital Markets is named among the joint book-runners for the proposed equity offering, reflecting a multi-bank syndicate supporting near-term liquidity needs (BioSpace press release, Mar 9, 2026).

William Blair

William Blair acted as a joint book-running manager on the proposed $75.0 million offering, reinforcing CTNM’s reliance on a diversified syndicate for capital formation (BioSpace press release, Mar 9, 2026).

Jones

Jones is identified as a manager for the proposed offering, playing a supporting role in execution of the equity raise and syndicate distribution (BioSpace press release, Mar 9, 2026).

Johnson & Johnson

Johnson & Johnson is an active development partner in CTNM’s PIPE‑307 program, having begun recruiting approximately 124 adult participants for a Phase 2 trial (BizWire / FinancialContent distribution, Mar 6, 2025).

Janssen Pharmaceutica NV

Under a global license and development agreement, CTNM relies on Janssen Pharmaceutica NV (a Johnson & Johnson company) to develop PIPE‑307 for indications outside RRMS and to decide whether to advance the program after CTNM’s Phase 2 VISTA trial, making Janssen a strategic gatekeeper for that asset’s future (BizWire / FinancialContent distribution, Mar 6, 2025).

WuXi AppTec

Contineum names WuXi AppTec as the CMO currently manufacturing the API for PIPE‑791 in China, and warns that a delay or disruption at this sole third‑party manufacturer could materially affect clinical supplies and program timelines (CTNM 10‑K, filed Dec 31, 2024).

(Each relationship above is documented in CTNM public disclosures or press releases; see the cited filings and press reporting for primary context.)

Explore detailed counterparty profiles and relationship risk scoring at https://nullexposure.com/ to quantify concentration and supplier criticality.

Investment implications: runway, dilution, and operational risk

CTNM’s near‑term financing and supplier posture create a two‑front risk/reward profile for investors. The planned ~$75M equity offering — underwritten by a syndicate of major firms — reduces immediate liquidity stress but increases dilution exposure if clinical readouts do not advance valuation. Concurrently, the sole-source manufacturing of PIPE‑791 in China (WuXi AppTec) and the license structure with Janssen for PIPE‑307 impose binary operational dependencies: manufacturing continuity and partner development decisions will directly shape program value realization.

  • Capital markets signal. The presence of top-tier book‑runners (Goldman, RBC, Stifel, William Blair, Leerink) communicates syndicate confidence in marketability but also acknowledges the need for fresh capital to fund trials. (BioSpace, Mar 2026)
  • Partner risk. Janssen/Johnson & Johnson control development scope for PIPE‑307 beyond RRMS; their discretion is a gating factor for expansion of the asset’s indications. (BizWire, Mar 2025)
  • Supply shock exposure. The reliance on a single CMO in China for PIPE‑791 introduces a material single point of failure that can delay development timelines and force costly mitigation. (CTNM 10‑K, FY2024)

What operators and procurement teams should track

  • Confirm contract terms and alternative supplier transition plans for the WuXi engagement, including lead times and tech transfer readiness.
  • Monitor milestone cadence and decision windows in the Janssen license agreement that could trigger partner advancement or termination.
  • Watch syndicate pricing and placement progress on the $75M offering as a proxy for market appetite and implied financing runway.

Bottom line and next steps

Contineum’s supplier map combines a syndicate-backed financing strategy with material operational concentration in manufacturing and partner-controlled development rights that together determine near-term value creation. For investors this translates into high upside tied to clinical success, coupled with distinct supplier and partner execution risks.

For a deeper, interactive supplier risk assessment and to download the full counterparty list, visit https://nullexposure.com/. For ongoing alerts and portfolio-level tracking of CTNM counterparties, see https://nullexposure.com/ for subscription options and tailored reporting.